Neuphoria Therapeutics (NEUP) Receivables - Net (2020 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Receivables - Net of $1.6 million for Q1 2026, up 6427.9% year-over-year from $24592.0 in Q1 2025, and up 44.64% quarter-over-quarter from $1.1 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Receivables - Net (2020 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Receivables - Net for 7 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Net rose 6427.9% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (up 6427.9% YoY), while the FY2025 annual figure was $11948.0, down 90.58% from the prior year.
- Receivables - Net improved to $1.6 million in Q1 2026 per NEUP's latest filing, from $1.1 million in the prior quarter.
- Across five years, Receivables - Net topped out at $1.6 million in Q1 2026 and bottomed at $1758.0 in Q3 2025.
- Historically, Receivables - Net has averaged $350732.3 across 5 years, with a median of $81029.5 in 2022.
- Annual changes were most pronounced in 2025 — Receivables - Net plunged 98.48% — and 2026, when it soared 6427.9%.
- Neuphoria Therapeutics' Receivables - Net stood at $46099.0 in 2022, then soared by 831.2% to $429272.5 in 2023, then plunged by 91.72% to $35561.0 in 2024, then soared by 3021.14% to $1.1 million in 2025, then surged by 44.64% to $1.6 million in 2026.
- Business Quant data shows NEUP's Receivables - Net at $1.6 million in Q1 2026, $1.1 million in Q4 2025, and $1758.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Neuphoria Therapeutics | 21.37 Mn | 1.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.61 Mn |
| Mar 31, 2026 | 1.61 Mn |
| Dec 31, 2025 | 1.11 Mn |
| Dec 31, 2025 | 1.11 Mn |
| Sep 30, 2025 | 1,758.00 |
| Sep 30, 2025 | 1,758.00 |
| Jun 30, 2025 | 11,948.00 |
| Jun 30, 2025 | 11,948.00 |
| Mar 31, 2025 | 24,592.00 |
| Mar 31, 2025 | 24,592.00 |
| Dec 31, 2024 | 35,561.00 |
| Dec 31, 2024 | 35,561.00 |
| Sep 30, 2024 | 115,960.00 |
| Sep 30, 2024 | 115,960.00 |
| Jun 30, 2024 | 126,884.00 |
| Jun 30, 2024 | 126,884.00 |
| Jun 30, 2023 | 429,272.54 |
| Jun 30, 2023 | 429,272.54 |
| Jun 30, 2022 | 46,099.03 |
| Jun 30, 2022 | 46,099.03 |